HistologiX Ltd is a research-focused biotechnology company established in 2005, operating from its headquarters at Building R3, Biocity Nottingham, Nottingham, NG1 1GF. The company’s core business revolves around the development and commercialization of novel biotechnological solutions. HistologiX specializes in identifying, characterizing, and utilizing unique biological markers for diagnostic and therapeutic applications. Currently, HistologiX focuses primarily on research and experimental development, with a strong emphasis on advancements within the pharmaceutical and medical diagnostics sectors. The company’s activities encompass a range of projects, including genetic sequencing, protein analysis, and the creation of novel biomarkers. HistologiX’s strategic location in Nottingham, UK, positions it within a region with a significant biotechnology industry. The company’s SIC codes encompass research and experimental development on biotechnology, as well as potentially related activities within areas such as genetic engineering and molecular biology. HistologiX is currently operating as an active company with a skilled workforce and a commitment to innovation. The company’s international presence is currently limited to no international operations.

HistologiX Ltd is a research-focused biotechnology company established in 2005, operating from its headquarters at Building R3, Biocity Nottingham, Nottingham, NG1 1GF. The company’s core business revolves around the development and commercialization of novel biotechnological solutions. HistologiX specializes in identifying, characterizing, and utilizing unique biological markers for diagnostic and therapeutic applications. Currently, HistologiX focuses primarily on research and experimental development, with a strong emphasis on advancements within the pharmaceutical and medical diagnostics sectors. The company’s activities encompass a range of projects, including genetic sequencing, protein analysis, and the creation of novel biomarkers. HistologiX’s strategic location in Nottingham, UK, positions it within a region with a significant biotechnology industry. The company’s SIC codes encompass research and experimental development on biotechnology, as well as potentially related activities within areas such as genetic engineering and molecular biology. HistologiX is currently operating as an active company with a skilled workforce and a commitment to innovation. The company’s international presence is currently limited to no international operations.